Stryker Q4 Earnings Announcement Scheduled
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 16h ago
0mins
Source: seekingalpha
- Earnings Release Date: Stryker (SYK) is set to announce its Q4 earnings on January 29th after market close, with an expected EPS of $4.40, reflecting a 9.7% year-over-year increase, which will further solidify its market position in the medical device sector.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $7.12 billion, representing a 10.6% year-over-year growth, indicating a strong revenue growth momentum driven by sustained market demand and product innovation.
- Historical Performance: Over the past two years, Stryker has beaten EPS estimates 100% of the time and revenue estimates 88% of the time, showcasing its robust profitability and market adaptability, which enhances investor confidence.
- Analyst Estimate Changes: In the last three months, EPS estimates have seen 12 upward revisions and 8 downward revisions, while revenue estimates experienced 19 upward revisions and 3 downward revisions, reflecting optimistic market sentiment regarding Stryker's future performance.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on SYK
Wall Street analysts forecast SYK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYK is 430.32 USD with a low forecast of 390.00 USD and a high forecast of 465.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 357.830
Low
390.00
Averages
430.32
High
465.00
Current: 357.830
Low
390.00
Averages
430.32
High
465.00
About SYK
Stryker Corporation is a medical technology company. The Company offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics products primarily include implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. The Company also offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Stryker Q4 Earnings Announcement Scheduled
- Earnings Release Date: Stryker (SYK) is set to announce its Q4 earnings on January 29th after market close, with an expected EPS of $4.40, reflecting a 9.7% year-over-year increase, which will further solidify its market position in the medical device sector.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $7.12 billion, representing a 10.6% year-over-year growth, indicating a strong revenue growth momentum driven by sustained market demand and product innovation.
- Historical Performance: Over the past two years, Stryker has beaten EPS estimates 100% of the time and revenue estimates 88% of the time, showcasing its robust profitability and market adaptability, which enhances investor confidence.
- Analyst Estimate Changes: In the last three months, EPS estimates have seen 12 upward revisions and 8 downward revisions, while revenue estimates experienced 19 upward revisions and 3 downward revisions, reflecting optimistic market sentiment regarding Stryker's future performance.
Continue Reading
Stryker Corp Dividend and Options Analysis
- Dividend Expectation Analysis: Stryker Corp's dividend history suggests that despite profitability fluctuations, the recent dividend may sustain a 1% annualized yield, reflecting the company's stable financial performance and commitment to shareholders.
- Volatility Assessment: With a trailing twelve-month volatility of 21% calculated from the last 251 trading days, this provides investors a basis for evaluating risk versus reward when considering selling covered calls at the $380 strike.
- Options Market Dynamics: On Tuesday, the put volume among S&P 500 components reached 802,997 contracts, while call volume hit 1.61 million, resulting in a put:call ratio of 0.50, indicating a preference for calls among investors, which may signal optimism regarding Stryker's future performance.
- Options Trading Trends: The current high call volume relative to the long-term median put:call ratio of 0.65 suggests a bullish market sentiment, with investors actively seeking to capitalize on Stryker's potential upside.
Continue Reading